Nydus R&D

Nydus R&D is revolutionizing preclinical drug testing with the first patient-relevant brainstem organoid (BrO) platform, designed to accurately model Diffuse Midline Glioma (DMG) — the deadliest pediatric brain cancer. This breakthrough, animal-free technology replicates the cellular complexity and treatment response of human brain tissue, enabling drug developers to test therapies with unprecedented precision and predict clinical outcomes more reliably.

Developed by scientists from the Princess Máxima Center for Pediatric Oncology and Oncode Institute, Nydus R&D combines expertise in organoid engineering, bioprinting, and translational cancer biology. The company aims to set a new gold standard for brainstem disease modeling, with future expansion into other brain cancers, neurodegenerative disorders, and in-house drug discovery.